The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Connecticut for 2022. Connecticut is home to some of the best healthcare services in the country, coming in at #3 in U.S. News & World Report’s rankings measuring how well states are meeting citizens' health care needs. It is also home to some of the most innovative, cutting-edge healthcare technology companies, which are revolutionizing the way we tackle health challenges of all types. The awardees on this list have been responsible for leading these companies—not only to profitability, but to life-changing breakthroughs.
As Vice President and Head of Clinical Development, Scott Rottinghaus is driving Alexion Pharmaceuticals toward its goal of transforming the lives of people living with rare diseases and devastating conditions. CEO Vlad Coric’s Biohaven Pharmaceuticals is on its way to using certain glutamate modulating agents in the treatment of neuropsychiatric disorders. And Founder and CEO Eric Schadt’s Sema4 is transforming healthcare by using AI and machine learning to build dynamic models of human health and define optimal, individualized health trajectories.
Being sandwiched between the major metropolitan areas of New York City and Boston, Connecticut can sometimes be overlooked, but the leaders on this year’s list and the company’s they represent demonstrate that Connecticut is a powerhouse in its own right when it comes to the healthcare technology industry. Please join us in celebrating The Top 25 Healthcare Technology Leaders of Connecticut for 2022.
1. Scott Rottinghaus
Company: Alexion Pharmaceuticals, Inc.
Title: Vice President and Head of Clinical Development, Hematology, and Nephrology
Scott Rottinghaus is Vice President and Head of Clinical Development, Hematology, and Nephrology for Alexion Pharmaceuticals, Inc., a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies. Its mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. Alexion’s passion drives it to continuously innovate and create meaningful value in all it does. In doing so, it changes lives for the better.
Rottinghaus first got his start in 2007 as a senior director at Pfizer, before eventually rising to assistant clinical professor of medicine at Yale University School of Medicine, his most recent position prior to joining Alexion. Rottinghaus graduated from the Mayo Clinic School of Medicine with an MD, from the University of Cambridge with an MS in biology, and from Kansas State University with an undergraduate degree in biology.
2. Jean-Claude Marshall
Company: Moderna
Title: Vice President and Head of Clinical Biomarkers
Jean-Claude Marshall is a Vice President and Head of Clinical Biomarkers at Moderna. He first joined the company in 2021. Moderna believes messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, Moderna believes mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. It’s pioneering a new class of medicines made using mRNA.
Previously, Marshall was head of clinical biomarker labs at Pfizer, and before that a research and CLIA lab manager at Catholic Health Initiative, Center for Translational Research. Earlier in his career, he worked with the National Institutes of Health as a cancer research fellow. Marshall earned a PhD and MS in ophthalmic pathology, and an undergraduate degree in anatomy and cellular biology from McGill University.
3. Susie Robinson
Company: Signant Health
Title: Chief People Officer
Susie Robinson is Chief People Officer for Signant Health, an evidence generation company. It is focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, more than 400 sponsors and CROs of all sizes—including all Top 20 pharma—have trusted Signant solutions for remote and site-based eCOA, eConsent, RTSM, supply chain management, and data quality analytics.
Before joining Signant Health, Robinson founded and was Principal, Advisor, and Interim Executive at Human Capital Architects, and before that Chief Human Resources Officer at Purdue Pharma L.P. Earlier in her career, she worked with B. Braun Medical as Chief Human Resources Officer. Robinson graduated from California State University, Fullerton with an undergraduate degree in psychology.
4. Henry Izawa
Company: FUJIFILM Healthcare Americas Corporation
Title: President and Chief Executive Officer
Henry Izawa is the President and CEO of FUJIFILM Healthcare Americas Corporation, a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. FUJIFILM’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery.
Fujifilm’s artificial intelligence initiative combines Fujifilm’s rich image-processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. Izawa started out at FUJIFILM as a marketing manager for FUJIFILM GmbH before becoming director of FUJIFILM France.
5. Vlad Coric
Company: Biohaven Pharmaceuticals
Title: Chief Executive Officer
Vlad Coric is the Chief Executive Officer of Biohaven Pharmaceuticals. He first joined the company in 2015. Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. It has obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders.
The mission of Biohaven is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Previously, Coric was group director of global clinical research at Bristol-Myers Squibb and associate clinic professor at the Yale School of Medicine.
6. Lisa Dunkle
Company: NOVAVAX INC
Title: Vice President of Clinical Research
Lisa Dunkle is the Vice President of Clinical Research at NOVAVAX INC, a clinical-stage biotechnology company focused on the discovery and development of innovative medicines. It’s making a difference in the health of people around the world by producing next generation vaccines that are accessible to more people.
Dunkle first got her start in 1976 as a Professor of Pediatrics and Microbiology at the St. Louis University School of Medicine. From there, she went on to Bristol-Myers Squibb, before eventually rising to Clinical Program Team Leader—Respiratory at Protein Sciences, a Sanofi Company, her most recent position prior to joining NOVAVAX INC. Dunkle graduated from The Johns Hopkins University School of Medicine with an MD and from Wellesley College with an undergraduate degree in biological sciences.
7. Eric Schadt
Company: Sema4
Title: Founder and Chief Executive Officer
Eric Schadt is the Founder and Chief Executive Officer of Sema4, a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
Schadt first got his start in 1998 as a senior research scientist at Roche Bioscience. From there, he went on to Rosetta Inpharmatics, before eventually rising to Chief Scientific Officer at Pacific Biosciences, his most recent position prior to joining Sema4. Schadt graduated from the University of California, Los Angeles with a PhD in biomathematics, from the University of California, Davis with an MA in pure Mathematics, and from California Polytechnic State University-San Luis Obispo with an undergraduate degree in applied mathematics and computer science.
8. Sean Mackay
Company: IsoPlexis
Title: Co-Founder and Chief Executive Officer
Sean Mackay is the Co-Founder and Chief Executive Officer of IsoPlexis. He first joined the company in 2012. IsoPlexis is a life science technology company that develops a single-cell detection system identifying patient immune responses. The future of immune medicine holds promise for lasting and durable impact on many diseases; IsoPlexis’ high resolution systems are powering the development and further personalization of these curative medicines.
Previously, Mackay was a senior associate at Lazard Freres & Co. and an analyst at Piper Jaffray. He founded a boutique advisory investment bank called Spring Hill, which was absorbed by Lazard. He earned an MBA from Yale School of Management and an undergraduate degree in economics from The Wharton School.
9. Steve Weiss
Company: Arvinas
Title: Senior Vice President and Chief Human Resources Officer
Steve Weiss first joined Arvinas in 2018 and he currently serves as the Senior Vice
President and Chief Human Resources Officer. Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. At Arvinas, Weiss is responsible for overseeing all aspects of human resources, including talent acquisition, total rewards, organization and leadership development, diversity and inclusion, and engagement. With more than 25 years of global experience in diverse industries, Weiss has achieved results within biotechnology, diagnostic imaging, asset management, legal, and financial services.
Prior to joining Arvinas, Weiss served as Executive Director of Human Resources at Alexion Pharmaceuticals. Before Alexion, he held roles of increasing responsibility at Hartford Investment Management, United Technologies, General Electric, and Sullivan &
Cromwell. Weiss earned a bachelor of science from the University of Kansas.
10. Angela Cacace
Company: Arvinas
Title: Senior Vice President of Neuroscience and Platform Biology
Angela Cacace is the Senior Vice President of Neuroscience and Platform Biology at Arvinas. She first joined the company in 2018 as Vice President of Neuroscience and Platform Biology. Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Previously, Cacace was vice president of biology at Fulcrum Therapeutics and before that director of genetically defined diseases at Bristol-Myers Squibb. Earlier in her career, she worked with the National Cancer Institute as a postdoctoral fellow. Cacace earned a PhD in pharmacology from the Columbia University Vagelos College of Physicians and Surgeons and an undergraduate degree in biology from Fairfield University.
11. Richard Blackburn
Company: Azurity Pharmaceuticals
Title: Chief Executive Officer
Richard Blackburn is the Chief Executive Officer of Azurity Pharmaceuticals, a privately held, specialty pharmaceutical company that focuses on products that meet the specific needs of underserved patient segments. Its products have benefited millions of patients whose needs are not served by other commercially available therapies.
Before joining Azurity Pharmaceuticals, Blackburn was Global President of Inflammation and Immunology at Pfizer, and before that a senior marketing manager at Parke-Davis. Earlier in his career, he worked with Sterling Winthrop Pharmaceuticals as a medical representative and sales manager. Blackburn graduated from Durham University with an undergraduate degree in natural sciences.
12. Saqib Islam
Company: SpringWorks Therapeutics
Title: Chief Executive Officer
Saqib Islam is the Chief Executive Officer of SpringWorks Therapeutics. He first joined the company in 2017 as Chief Financial Officer and Chief Business Officer. SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.
Previously, Islam was Chief Business Officer at Moderna Therapeutics, and before that Executive Vice President and Chief Strategy Officer at Alexion Pharmaceuticals, Inc. Earlier in his career, he worked with Morgan Stanley as a managing director of investment banking. Islam earned a JD in law from Columbia University and an undergraduate degree from McGill University.
13. Bob Reinhardt
Company: Defibtech, LLC
Title: President and Chief Executive Officer
Bob Reinhardt is the President and Chief Executive Officer of Defibtech, LLC, a leader and innovator in the design and manufacture of automated external defibrillators (AEDs) and other lifesaving resuscitation products, such as the new automated chest compression device Lifeline ARM. By using advanced design and manufacturing techniques, Defibtech provides value-oriented, easy-to-use solutions with high quality and reliability. With more than 450,000 defibrillators shipped worldwide in various language configurations, Defibtech has drawn accolades and won numerous awards for innovative product design, growth, quality, and services.
Reinhardt first got his start in 1985 as a research and development engineer at Meadox Medicals. From there, he went on to Guidant, before eventually rising to Group Vice President of Commercial Logistics at Olympus Corporation of the Americas, his most recent position prior to joining Defibtech, LLC. Reinhardt graduated from Rensselaer Polytechnic Institute with an MS in biomedical engineering and from Tulane University with an undergraduate degree in biomedical engineering.
14. Kristin King
Company: Defibtech, LLC
Title: Vice President of Corporate Development
Kristin King is the Vice President of Corporate Development and Mergers & Acquisitions for Defibtech, LLC, a leader and innovator in the design and manufacture of automated external defibrillators (AEDs) and other lifesaving resuscitation products, such as the new automated chest compression device Lifeline ARM. By using advanced design and manufacturing techniques, Defibtech provides value-oriented, easy-to-use solutions with high quality and reliability.
Before joining Defibtech, LLC, King was Head of AIP, Business Development, and M&A at Ansell, and before that an interim director and senior brand manager at BD Medical. Earlier in her career, she worked with Northeast Utilities, Millstone Nuclear Power Station as a project leader of electrical design engineering. King graduated from the NYU Stern School of Business with an MBA in finance and marketing and from Syracuse University with an undergraduate degree in bioengineering and mathematics.
15. Peter Arn
Company: ROM Technologies Inc
Title: Co-Founder, Chairman, and Chief Executive Officer
Peter Arn co-founded ROM Technologies Inc in 2014 and is currently its Chairman and Chief Executive Officer. ROM Technologies Inc is the developer of a breakthrough, patented medical technology for knee and hip rehabilitation. The ROM technology enables knee and hip patients to recover 50% faster, saving money for patients, medical facilities, and payers.
Prior to joining ROM Technologies Inc, Arn was a Co-Founder and Chief Operating Officer of GoChuckGo, and before that a Co-Founder and Managing Partner at Hoffman Financial Group. Earlier in his career he worked with Ross Mortgage Co as a loan officer and was Founder and CEO of Calvin Capital Corporation.
16. Nicole Sandford
Company: Aspira Women’s Health
Title: President and Chief Executive Officer
Nicole Sandford is President and Chief Executive Officer of Aspira Women’s Health, a Connecticut-based bioanalytical-based women’s health company focused on gynecologic disease. Aspira’s current ovarian cancer tests help women and their doctors assess malignancy risk prior to surgery. Nicole has extensive experience as an innovator and business leader, as well as a sought-after advisor to CEOs and Boards on strategy, operations, human capital, governance, and risk.
Prior to joining Aspira, Nicole spent nearly three decades at global consultancy Deloitte, where she led multiple businesses in the life sciences/healthcare, financial services, and consumer industries. She is a prior board chair of Girl Scouts of Connecticut and board member of many other charitable and non-profit organizations. She is an emeritus member of the Weinberg Center at the University of Delaware and member of the Greenwich Hospital Breast Cancer Accreditation Committee. In 2022, Nicole was named to NACD’s Directorship 100. She has also received the Yale School of Management’s “Rising Star” Award and The International Alliance for Women’s (TIAW) “World of Difference Award.” She received a BBA in accounting from Niagara University.
17. Henri Lichenstein
Company: Drug Farm Inc
Title: Chief Executive Officer
Henri Lichenstein is the Chief Executive Officer of Drug Farm Inc. As a China and U.S.-based biotech, Drug Farm is developing first-in-class drugs in the fields of hepatitis B, cancer, and autoimmune diseases using its platform mouse genetics and AI technologies.
Prior to Drug Farm, Lichenstein was a program leader at Amgen. From there, he went on to CuraGen Corporation, before eventually rising to CEO at AI Therapeutics, his most recent position prior to joining Drug Farm Inc in 2020. Lichenstein graduated from UC Santa Barbara with a PhD in biochemistry and molecular biology.
18. Vimal Mehta
Company: BioXcel Corporation
Title: Co-Founder, Chairman, and Chief Executive Officer
Vimal Mehta co-founded BioXcel Corporation in 2006 and is currently its Chairman and Chief Executive Officer. BioXcel Corporation is a biopharmaceutical company pioneering the application of big data analytics and machine learning-based artificial intelligence integrated with drug development expertise to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development. Its goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need.
Preceding BioXcel, Mehta worked as a business development manager at CuraGen Corporation, before eventually rising to senior vice president at Inpharmatica, his most recent position prior to co-founding BioXcel Corporation. Mehta graduated from Delhi University with a PhD in medicinal and pharmaceutical chemistry and a master’s in organic chemistry. He was a postdoctoral fellow in chemistry at the University of Montpellier.
19. Vikram Butani
Company: KUBTEC Medical Imaging
Title: Founder and Chief Executive Officer
Vikram Butani is the Founder and Chief Executive Officer of KUBTEC Medical Imaging, a leading provider of high quality digital X-ray imaging systems for clinical, pathology, forensic, and scientific research. It is challenging the status quo of breast cancer surgery and is committed to reducing the excessive number of re-excision surgeries. Through continuous research and development of its proprietary 3D tomosynthesis technology, KUBTEC is empowering surgeons with immediate visualization of surgical margins in the operating theater, helping to reduce re-excision rates, preserve healthy breast tissue, and ultimately improve patient outcomes.
Butani began his tenure as CEO of KUBTEC in 2005 when he founded the company with his wife, Preeti. The couple initially sold their products out of their Fairfield, CT home.
20. Lan Li
Company: WuXi AppTec
Title: Vice President and Global Head of Bioanalysis
Lan Li is the Vice President and Global Head of Bioanalysis at WuXi AppTec. As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industries to advance discoveries and deliver groundbreaking treatments to patients.
Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development, and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. Prior to WuXi AppTec, Li worked for Alexion Pharmaceuticals, Inc. starting as a research scientist and working up to director of research strategy and portfolio management. Li studied at the University of Nebraska Medical Center.
21. Bo Qu
Company: TCG GreenChem Inc.
Title: Associate Vice President and Head of Technology and Process Chemistry
Dr. Bo Qu is the Associate Vice President of Process Chemistry and Technology at TCG
GreenChem, Inc. The company’s vision is to catalyze the development of novel, effective, and
affordable drugs with a “First Time Right” approach to create one of best global innovative
Contract Development Organizations (iCDMOTM) that partners with the pharmaceutical sectors and wider industries, delivering APIs through green, sustainable, and innovative technologies with a global footprint.
Dr. Qu has more than 16 years of experience in the pharmaceutical industry in the drug development arena. She started at Boehringer Ingelheim Chemical Development. After a series of accomplishments, she was promoted to Senior Principal Scientist. She developed many new and practical catalytic and asymmetric transformations for sustainable and cost-effective drug development. Recently, she discovered a novel chiral P,N ligand class named BoQphos to produce valuable enantiomerically pure piperidine-containing heterocycles for drug discovery and development. She has authored more than 100 peer-reviewed publications. In 2020, she was invited to join the scientific advisory board of the International Symposium on Homogeneous Catalysis. In 2021, she was appointed as an Editorial Board member of Organic Reactions. Dr. Qu received her postdoctoral training in mechanistic studies of organic reactions at Cornell University. She earned a PhD in methodology development of transition metal complexes and applications toward catalytic reactions from the University of South Carolina, and a MS degree in chemistry from the University of Science and Technology of China.
22. Bryan Jennings
Company: TME Pharma
Title: Chief Financial Officer
Bryan Jennings is the Chief Financial Officer for TME Pharma. Based in Amsterdam with operations in Berlin, Germany, TME Pharma's oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.
Jennings has been instrumental in refocusing TME Pharma’s strategic and financial direction while working with the company’s outstanding CEO, Aram Mangasarian. Prior to joining TME Pharma, Jennings served as Chief Financial Officer of Peptilogics, Inc. Previously, he was Chief Financial Officer for several private biotech firms including ChemomAb Ltd., Beren Therapeutics, Rational Vaccines, and KAHR Medical.
Prior to his CFO roles in biotech, Jennings was a senior member of the management team and managing director at Morgan Stanley. In addition to running the firm's capital markets team in the Americas, he also spent significant time in the firm's mergers and acquisitions practice and worked for several years in London covering technology and healthcare companies as well. Earlier, Jennings began his Wall Street career and spent several years as an analyst at Goldman Sachs. He received his Bachelor of Arts in economics and political science from Williams College and his MBA in Finance and Accounting from the Kellogg School of Management at Northwestern University.
23. Bridget Martell
Company: Artizan Biosciences, Inc.
Title: President and Chief Executive Officer
Bridget Martell has been the President and Chief Executive Officer of Artizan Biosciences, Inc. since 2021. Artizan Biosciences is a biotechnology company creating a new class of transformative precision therapeutics that target and block the root causes of diverse, serious diseases triggered by intestinal inflammation. Founded with IgA-SEQ™ technology and preeminent immunobiology expertise from Yale University, Artizan leverages the microbiome as a drug discovery tool to identify and characterize microbial drivers of disease. Capable of using both novel small molecule and monoclonal antibody approaches, the company modulates intestinal imbalances by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract.
Previously, Martell was a senior scientific advisor at Kura Oncology, Inc., and before that an associate clinical professor at Yale-New Haven Hospital. Earlier in her career, she worked with ImmunoGen as a research associate. Martell earned an MD from the Chicago Medical School at the Rosalind Franklin University of Medicine and Science, an MA in biochemistry and molecular immunology from Boston University School of Medicine, and an undergraduate degree in microbiology from Cornell University.
24. Reza Amin
Company: Bastion Health
Title: Founder and Chief Executive Officer
Reza Amin is the Founder and Chief Executive Officer of Bastion Health, a digital health platform pioneering technology to impact and enhance male reproductive health and prostate health. It believes that healthcare should be accessible, affordable, and comprehensive, so it created at-home testing kits for men along with a platform that connects them with physicians and guides them through their journey to better reproductive and prostate health.
Amin is also a co-founder of Encapsulate. Before joining Bastion Health, Amin was a research assistant and global entrepreneurship fellow at the University of Connecticut. Amin graduated from the University of Connecticut with a PhD in mechanical engineering and a master’s in global entrepreneurship, from Sharif University of Technology with a master’s in mechatronics engineering, and from Savitribai Phule Pune University with an undergraduate degree in electronics.
25. Sasha Bakhru
Company: Perosphere Technologies
Title: Founder and Chief Executive Officer
Sasha Bakhru is the Founder and Chief Executive Officer of Perosphere Technologies, a private medical diagnostics company focused on developing next-generation coagulation tests for the hospital setting. Their point-of-care (PoC) coagulometer technology platform provides an unprecedented view of a patient's overall coagulation status and enables physicians to rapidly measure a patient's whole blood clotting time in the ER at a patient's bedside, and also in the outpatient setting. Perosphere received a first regulatory clearance for their PoC coagulometer in the EU and will be applying for their U.S. clearance this year.
In addition to his duties at Perosphere Technologies, Bakhru is an adjunct assistant professor of medical science at Brown University, advisor to several biotech startups, including Amylyx Pharmaceuticals, and a fellow of the American Institute for Medical and Biological Engineering. Bakhru previously co-founded and was CTO, CSO, and Senior Executive VP of the pharmaceutical company Perosphere Inc. (acquired by AMAG Pharmaceuticals in 2019). Bakhru earned a PhD in biomedical engineering from Carnegie Mellon University—where he was awarded the Entrepreneur of the Year alumni prize in 2009—an MSE in materials science and engineering from The Johns Hopkins University, and a BS in biomedical engineering from Columbia University.
